SCHEMBL16176709

SCHEMBL16176709

COC(=O)C(N(C)C(=O)OC(C)(C)C)C(C)(C)c1ccc(CNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
MAPT P10636 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
RECQL P46063 1/20 0.40
GAA P10253 2/20 0.40
HDAC1 Q13547 2/20 0.39
POLB P06746 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
XBP1 P17861 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
SDCBP O00560 1/20 0.38
SDC2 P34741 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
EPHX2 P34913 2/20 0.37
NR1H4 Q96RI1 2/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16176710 1.00 NAMPT (0.42) NAMPTL3MBTL1MAPTNPSR1RECQL
SCHEMBL20723953 0.90 NAMPT (0.43) NAMPTL3MBTL1MAPTNPSR1RECQL
SCHEMBL19282696 0.90 NAMPT (0.43) NAMPTL3MBTL1MAPTNPSR1RECQL
SCHEMBL16183161 0.86 L3MBTL1 (0.39) L3MBTL1HDAC1TDP1
SCHEMBL6805608 0.81 AAK1 (0.41) MAPTRECQLPOLBTDP1MEN1
SCHEMBL16176663 0.81 AAK1 (0.41) MAPTRECQLPOLBTDP1MEN1
SCHEMBL57636 0.80 MMP13 (0.40) NPSR1HDAC1MEN1KMT2ARAB9A
SCHEMBL88675 0.80 MMP13 (0.40) NPSR1HDAC1MEN1KMT2ARAB9A
SCHEMBL16176767 0.80 CHRNB2 (0.40) POLBKMT2AEPHX2
SCHEMBL7066900 0.80 SRD5A2 (0.38) MAPTGAAHDAC1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12303544-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS BC INC. (CA) 2025-05-20 US disclosed
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2023-12-07 US disclosed
US-11617777-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS BC INC. 2023-04-04 US disclosed
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2019-09-05 US disclosed
CN-110143999-A Have cytotoxicity and antimitotic compound and its application method 酵活有限公司 2019-08-20 CN disclosed
EP-2968440-B1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS INC (CA) 2019-06-05 EP disclosed
CN-105358174-B Cytotoxic and antimitotic compounds and methods of use thereof 酵活有限公司 2019-03-15 CN disclosed
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2019-02-12 US disclosed
US-9522876-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2016-12-20 US disclosed
US-20160038606-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2016-02-11 US disclosed
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2014-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11617777-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, BOD1L1 NAMPT 2050/4885L3MBTL1 511/4885MAPT 838/4885
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, CCNB2, CCNB3 NAMPT 1774/4885L3MBTL1 211/4885MAPT 1616/4885
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, CCNB2 NAMPT 2062/4885L3MBTL1 465/4885MAPT 692/4885
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 NAMPT 2050/4885L3MBTL1 511/4885MAPT 838/4885
US-12303544-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, BOD1L1 NAMPT 2050/4885L3MBTL1 511/4885MAPT 838/4885
US-20230390354-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 NAMPT 2050/4885L3MBTL1 511/4885MAPT 838/4885
US-20160038606-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, CCNB2 NAMPT 2062/4885L3MBTL1 465/4885MAPT 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.